Topic: amyotrophic lateral sclerosis
Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.
Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.
Targeting a cell process that promotes protein clumping could lead to new drugs for ALS.
AB Science says its drug candidate masitinib has slowed down progression in a late-stage trial, but its checkered development history means the reaction is muted.
University of Utah scientists found antisense drugs reversed symptoms in mouse models of ataxia and amyotrophic lateral sclerosis.
A Mayo Clinic-led team has landed on a protein that could serve as a marker in the development of new drugs for ALS.
SUNY Downstate researchers have developed a wearable device that allows ALS patients who are completely “locked in” to communicate.